Will AI Security Standards And Confidential Computing Moves Change Advanced Micro Devices' (AMD) Narrative?

• In recent days, the Linux Foundation said it is taking stewardship of TRACE, an open hardware-attested evidence standard for AI and confidential workloads co-developed by AMD, Intel, Microsoft, OPAQUE and TII, while Anjuna Security launched its Seaglass confidential computing platform on AMD EPYC CPUs using AMD Secure Virtualization.
• Together with fresh analyst enthusiasm for AMD’s role in AI server CPUs and agentic AI workloads, these moves highlight how AMD is tying its silicon to emerging standards and easier deployment paths for secure AI infrastructure.
• We’ll now examine how AMD’s TRACE work and SEV-powered confidential computing support could reshape the company’s investment narrative around AI infrastructure.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Advanced Micro Devices Investment Narrative Recap

To own AMD, you need to believe it can sustain strong data center and AI growth while justifying a premium multiple in a very competitive market. The TRACE standard and Anjuna’s SEV-based confidential computing launch reinforce AMD’s positioning in secure AI infrastructure, but they do not fundamentally change the near term focus on execution in AI GPUs and EPYC server CPUs, or the key risk that high expectations and rich earnings multiples leave little room for operational missteps.

The TRACE contribution to the Linux Foundation is the clearest tie-in to AMD’s push around secure, governed AI workloads. By co-developing a vendor neutral, hardware attested evidence layer for AI agents and confidential workloads, AMD is aligning its CPUs and accelerators with emerging compliance and governance requirements that matter to hyperscalers, enterprises, and sovereign projects. That supports the existing AI infrastructure catalyst while also underscoring the risk that standards and trust frameworks could shift and influence future deployment decisions.

Yet while optimism around TRACE and secure AI is high, investors should also be aware that...

Read the full narrative on Advanced Micro Devices (it's free!)

Advanced Micro Devices' narrative projects $137.4 billion revenue and $38.5 billion earnings by 2029. This requires 49.3% yearly revenue growth and a $32.0 billion earnings increase from $6.5 billion today.

Uncover how Advanced Micro Devices' forecasts yield a $612.84 fair value, a 28% upside to its current price.

Exploring Other Perspectives

While the consensus sees robust AI growth, the most cautious analysts worry that TRACE era AI demand may not offset rising risks, even with revenue once modeled at about US$88.2 billion and earnings near US$15.0 billion by 2029, so you should compare those more pessimistic assumptions with your own view of how this new AI security focus could shift the story.

Explore 27 other fair value estimates on Advanced Micro Devices - why the stock might be worth 43% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Advanced Micro Devices research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Advanced Micro Devices research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Advanced Micro Devices' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com